Table 1.
Examples of the different types of surfactants used in drug delivery.
| Surfactant Formulation | Therapeutic(s) Delivered | Medical Application | Ref. |
|---|---|---|---|
| Non-Ionic | |||
| SDC-PC (40 nm) |
Ciprofloxacin | ** | [34,35] |
| Sorbitan monostearate (Span 60) (77–84 nm) |
Policarpine HCl | Ocular | [33,36] |
| Tween 80 (46 to 114 nm) |
Curcumin | Brain | [37,38] |
| Brij 78 (90 to 120 nm) |
Doxorubicin | Oncology | [39,40] |
| Cationic | |||
| CKC (240 μm) |
Dexamethasone 21-disodium phosphate | Ocular | [41,42] |
| Sodium alginate-HPMC | Cripofloxacin Hydrochloride | Ocular | [43] |
| DTAB (60–90 nm) |
Meloxicam | Dermal Delivery | [44,45] |
| CPC (60–90 nm) |
Meloxicam | Dermal Delivery | [44,46] |
| Anionic | |||
| SLS (130–220 nm) |
Propranolol HCl | ** | [47,48] |
| ST (20 nm) |
Propranolol HCl | ** | [47,49] |
| SDS (110–250 nm) |
** | Transdermal drug delivery | [50,51] |
| DA (400 nm) |
(+)-catechin | Transdermal drug delivery | [52,53] |
| Amphoteric | |||
| pDoAo | Oxytetracycline | ** | [48,54] |
| LSB | ** | Transdermal drug delivery | [49,55] |
| Lecithin (611 nm) |
Doxorubicin Hydrochloride | ** | [56] |
| PSBMA (230–290 nm) |
Doxorubicin | Oncology | [57] |
N-((4-sulfamoyphenyl)carbamothyol)stearamide (SDC-PC), Poly(ethylene glycol) sorbitan monooleate (Tween 80), Poly(ethylene glycol) octadecyl ether (Brij 78), Cetalkonium chloride (CKC), hydroxypropylmethylcellulose (HPMC), Dodecyltrimethylammonium bromide (DTAB), Cetylpyridinium chloride monohydrate (CPC), Sodium lauryl sulfate (SLS), Sodium taurocholate (ST), Sodium dodecylsulfate (SDS), Deoxycholic acid (DA), p-dodecyloxybenzyldimethylamine N-oxide (pDoAo), Lauryl sulfonate betaine (LSB), Poly(sulfobetaine methacrylate) (PSBMA). ** These papers did not discuss the drug released or the potential medical applications of the self-assembled system of interest.